blood-cancer

Therapy-related AML rates have nearly tripled over 30 years as cancer survivor population grows.

Therapy-related acute myeloid leukemia (tAML) arises as a secondary malignancy from cancer treatments (chemotherapy, radiation). This Japanese study found that tAML incidence increased gradually but steadily over the past three decades, with rates almost tripling—driven by the growing population of…

Dan Manning

Dan Manning

— 1 min read
Share
Therapy-related AML rates have nearly tripled over 30 years as cancer survivor population grows.

Therapy-related AML rates have nearly tripled over 30 years as cancer survivor population grows.

Therapy-related acute myeloid leukemia (tAML) arises as a secondary malignancy from cancer treatments (chemotherapy, radiation). This Japanese study found that tAML incidence increased gradually but steadily over the past three decades, with rates almost tripling—driven by the growing population of cancer survivors who are living longer after treatment.

This trend has significant implications for survivorship care, particularly for patients who received alkylating agents or topoisomerase II inhibitors. tAML carries a poor prognosis and represents a growing clinical challenge.

Long-term survivors of common cancers (breast, lymphoma, prostate) are at particularly elevated risk.

Key Findings

  • tAML incidence rates nearly tripled over the past three decades in Japan
  • Rising rates driven by growing cancer survivor population
  • tAML carries poor prognosis
  • Long-term survivors of common cancers are most at risk
  • Growing clinical challenge as overall cancer survival improves

Implications

Oncologists treating patients with chemotherapy regimens known to cause tAML (especially alkylating agents) should counsel patients about long-term risk. Survivorship care plans should include monitoring for secondary hematological malignancies. Lower-risk chemotherapy regimens should be prioritized when clinically equivalent options exist.

Caveats

RSS news brief; limited methodological detail; abstract-only. Japan-specific data—may not fully reflect global trends. Specific cancer types driving tAML and treatment regimens involved not detailed in abstract.

Source: MedPage Hematology/Oncology — 2026-04-07

Read more